文献速递消化、代谢与肾脏急症

10 mg泼尼松龙治疗手骨关节炎6周结果(HOPE):双盲随机安慰剂对照试验

Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Lancet · 2019-11-11
一句话结论对伴滑膜炎症的手骨关节炎患者,口服10 mg泼尼松龙每日1次共6周可有效减轻手指疼痛且安全性良好。

HOPE研究为双盲随机安慰剂对照试验,在荷兰两个中心纳入92例有症状且超声显示远端/近端指间关节滑膜炎症或能量多普勒信号的手骨关节炎患者,随机接受10 mg泼尼松龙或安慰剂口服每日1次共6周,随后2周减量、6周随访。主要终点6周VAS手指疼痛较基线变化:泼尼松龙组-21.5(SD 21.7)vs 安慰剂组-5.2(SD 24.3),组间差异-16.5(95%CI -26.1至-6.9;P=0.0007)。非严重不良事件两组相似,严重不良事件泼尼松龙组1例(心肌梗死)、安慰剂组4例。作者认为10 mg泼尼松龙6周对伴炎症的手骨关节炎有效且安全,为临床提供短期治疗选择。

要点

  • 纳入标准:≥4个DIP/PIP关节有骨关节炎结节、至少1个DIP/PIP关节软肿胀或红斑、至少1个DIP/PIP关节能量多普勒阳性或超声滑膜增厚≥2级、100mm VAS手指疼痛≥30mm且在48小时NSAID洗脱期加重≥20mm。
  • 92例随机1:1接受泼尼松龙10 mg口服每日1次共6周(后2周减量)或安慰剂;6周VAS手指疼痛变化泼尼松龙组-21.5 vs 安慰剂组-5.2,组间差异-16.5(95%CI -26.1至-6.9;P=0.0007)。
  • 非严重不良事件两组相似;严重不良事件泼尼松龙组1例(心肌梗死),安慰剂组4例(感染性腿部血肿需手术、肠道手术、房颤需起搏器、症状性子宫肌瘤需子宫切除)。
  • 因不良事件停药:泼尼松龙组1例(2%,心肌梗死),安慰剂组3例(7%,肠道手术、感染性腿部血肿、莱姆病膝关节炎)。
  • 作者认为10 mg泼尼松龙6周对伴炎症的手骨关节炎有效且安全,为疾病 flare-up 患者提供新的短期治疗选择。

适用人群与场景

  • 成人有症状手骨关节炎患者,来自荷兰两个风湿科门诊。
  • 纳入需满足:≥4个DIP/PIP关节有骨关节炎结节;至少1个DIP/PIP关节软肿胀或红斑;至少1个DIP/PIP关节能量多普勒阳性或超声滑膜增厚≥2级;100mm VAS手指疼痛≥30mm且在48小时NSAID洗脱期加重≥20mm。
  • 排除原因主要为不符合一项或多项纳入标准,最常见为无滑膜炎症或NSAID洗脱后无flare-up。

诊断标准与关键阈值

  • 手骨关节炎伴炎症的纳入标准:≥4个DIP/PIP关节骨关节炎结节;至少1个DIP/PIP关节软肿胀或红斑;至少1个DIP/PIP关节能量多普勒阳性或超声滑膜增厚≥2级;100mm VAS手指疼痛≥30mm且在48小时NSAID洗脱期加重≥20mm。

处置流程与药物剂量

  • 泼尼松龙10 mg口服每日1次,共6周,随后2周减量方案,之后6周不服药随访。
  • 安慰剂对照。

研究设计与关键结果

  • 双盲随机安慰剂对照试验,在荷兰两个中心进行,149例评估资格,57例(38%)排除,92例(62%)随机1:1至泼尼松龙组46例和安慰剂组46例,均纳入改良意向治疗分析。
  • 6周VAS手指疼痛较基线变化:泼尼松龙组-21.5(SD 21.7)vs 安慰剂组-5.2(SD 24.3),组间差异-16.5(95%CI -26.1至-6.9;P=0.0007)。
  • 完成14周研究:泼尼松龙组42例(91%),安慰剂组42例(91%)。
  • 非严重不良事件两组相似;严重不良事件共5例:泼尼松龙组1例(心肌梗死),安慰剂组4例(感染性腿部血肿需手术、肠道手术、房颤需起搏器、症状性子宫肌瘤需子宫切除)。
  • 因不良事件停药4例(4%):泼尼松龙组1例(2%,心肌梗死),安慰剂组3例(7%,肠道手术、感染性腿部血肿、莱姆病膝关节炎)。

证据类型、等级与局限

  • 证据类型:双盲随机安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为10 mg泼尼松龙6周对伴炎症的手骨关节炎有效且安全,为临床提供新的短期治疗选择,适用于报告疾病flare-up的手骨关节炎患者。

指南或共识出处

  • 荷兰试验注册号NTR5263;资助:Dutch Arthritis Society。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hand osteoarthritis is a prevalent joint condition that has a high burden of disease and an unmet medical need for effective therapeutic options. Since local inflammation is recognised as contributing to osteoarthritic complaints, the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study aimed to investigate the efficacy and safety of short-term prednisolone in patients with painful hand osteoarthritis and synovial inflammation.

METHODS: The HOPE study is a double-blind, randomised, placebo-controlled trial. We recruited eligible adults from rheumatology outpatient clinics at two sites in the Netherlands. Patients were considered eligible if they had symptomatic hand osteoarthritis and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints. For inclusion, patients were required to have four or more DIP/PIP joints with osteoarthritic nodes; at least one DIP/PIP joint with soft swelling or erythema; at least one DIP/PIP joint with a positive power Doppler signal or synovial thickening of at least grade 2 on ultrasound; and finger pain of at least 30 mm on a 100-mm visual analogue scale (VAS) that flared up during a 48-h non-steroidal anti-inflammatory drug (NSAID) washout (defined as worsening of finger pain by at least 20 mm on the VAS). Eligible patients were randomly assigned (1:1) to receive 10 mg prednisolone or placebo orally once daily for 6 weeks, followed by a 2-week tapering scheme, and a 6-week follow-up without study medication. The patients and study team were masked to treatment assignment. The primary endpoint was finger pain, assessed on a VAS, at 6 weeks in participants who had been randomly assigned to groups and attended the baseline visit. This study is registered with the Netherlands Trial Registry, number NTR5263.

FINDINGS: We screened patients for enrolment between Dec 3, 2015, and May 31, 2018. Patients completed baseline visits and started treatment between Dec 14, 2015, and July 2, 2018, and the last study visit of the last patient was Oct 4, 2018. Of 149 patients assessed for eligibility, 57 (38%) patients were excluded (predominantly because they did not meet one or several inclusion criteria, most often because of an absence of synovial inflammation or of flare-ups after NSAID washout) and 92 (62%) patients were eligible for inclusion. We randomly assigned 46 (50%) patients to receive prednisolone and 46 (50%) patients to receive placebo, all of whom were included in the modified intention-to-treat analysis of the primary endpoint. 42 (91%) patients in the prednisolone group and 42 (91%) in the placebo group completed the 14-week study. The mean change between baseline and week 6 on VAS-reported finger pain was -21·5 (SD 21·7) in the prednisolone group and -5·2 (24·3) in the placebo group, with a mean between-group difference (of prednisolone vs placebo) of -16·5 (95% CI -26·1 to -6·9; p=0·0007). The number of non-serious adverse events was similar between the groups. Five serious adverse events were reported during our study: one serious adverse event in the prednisolone group (a myocardial infarction) and four serious adverse events in the placebo group (an infected traumatic leg haematoma that required surgery, bowel surgery, atrial fibrillation that required a pacemaker implantation, and symptomatic uterine myomas that required a hysterectomy). Four (4%) patients discontinued the study because of an adverse event: one (2%) patient receiving prednisolone (for a myocardial infarction) and three (7%) patients receiving placebo (for surgery of the bowel and for an infected leg haematoma and for Lyme disease arthritis of the knee).

INTERPRETATION: Treatment with 10 mg prednisolone for 6 weeks is efficacious and safe for the treatment of patients with painful hand osteoarthritis and signs of inflammation. The results of our study provide clinicians with a new short-term treatment option for patients with hand osteoarthritis who report a flare-up of their disease.

FUNDING: Dutch Arthritis Society.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kroon FPB, Kortekaas MC, Boonen A, et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet. 2019. PMID: 31727410. doi:10.1016/S0140-6736(19)32489-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。